PMID- 33860646
OWN - NLM
STAT- MEDLINE
DCOM- 20210429
LR  - 20210429
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 17 Suppl 3
DP  - 2021 Apr
TI  - Olaparib dose re-escalation in ovarian cancer patients who experienced severe 
      and/or uncommon adverse events: A case series.
PG  - 3-11
LID - 10.1111/ajco.13584 [doi]
AB  - AIM: Few real-world studies have reported detailed management and dose adjustment 
      strategies of adverse events (AEs) of ovarian cancer (OC) patients treated with 
      the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib. This case 
      series aimed to describe olaparib AEs in Chinese OC patients in real-life 
      settings and to explore dose modification strategies. METHODS: We conducted a 
      detailed examination of the clinical records of OC patients who were treated with 
      olaparib at the Gynecologic Oncology Unit in Hong Kong from September 2015 to 
      December 2019, including baseline characteristics, treatment outcomes, AEs, and 
      management strategies, particularly dose modifications. RESULTS: Nineteen 
      patients were included, with a median olaparib treatment duration of 12 (range: 
      3-30) months. For recurrent platinum-sensitive cases (n = 16), the median 
      progression-free survival was 16.0 months (95% confidence interval: 9.5-22.5). 
      Eighteen (95%) patients experienced AE(s) of any grade, including four (21%) who 
      experienced grade >/=3 AE(s). The most common AEs were as follows: nonhematologic 
      fatigue (68%), nausea (42%), vomiting (26%), decreased appetite (26%), dyspepsia 
      (21%), dizziness (21%), anemia (37%), neutropenia (26%), and thrombocytopenia 
      (21%). Four specific cases involving anemia, lower limb lymphedema, myeloid 
      neoplasm, and erythema nodosum are discussed separately. Eight patients required 
      dose interruption or reduction due to AEs, of which five patients attempted and 
      tolerated dose re-escalation. CONCLUSION: In this study, most AEs were mild, but 
      rare AEs were observed. In OC patients, olaparib AE management with dose 
      reductions followed by re-escalations was feasible, including for anemia.
CI  - (c) 2021 John Wiley & Sons Australia, Ltd.
FAU - Ngu, Siew-Fei
AU  - Ngu SF
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary 
      Hospital, Hong Kong.
FAU - Tse, Ka-Yu
AU  - Tse KY
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary 
      Hospital, Hong Kong.
FAU - Chu, Mandy M Y
AU  - Chu MMY
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary 
      Hospital, Hong Kong.
FAU - Ngan, Hextan Y S
AU  - Ngan HYS
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary 
      Hospital, Hong Kong.
FAU - Chan, Karen K L
AU  - Chan KKL
AD  - Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary 
      Hospital, Hong Kong.
LA  - eng
GR  - AstraZeneca Hong Kong/
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Phthalazines)
RN  - 0 (Piperazines)
RN  - WOH1JD9AR8 (olaparib)
SB  - IM
MH  - Adult
MH  - Carcinoma, Ovarian Epithelial
MH  - Drug-Related Side Effects and Adverse Reactions/*complications
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Ovarian Neoplasms/*complications/drug therapy
MH  - Phthalazines/*adverse effects/pharmacology
MH  - Piperazines/*adverse effects/pharmacology
OTO - NOTNLM
OT  - adverse drug event
OT  - anemia
OT  - dose-response relationship (drug)
OT  - olaparib
OT  - ovarian cancer
EDAT- 2021/04/17 06:00
MHDA- 2021/04/30 06:00
CRDT- 2021/04/16 06:59
PHST- 2021/04/16 06:59 [entrez]
PHST- 2021/04/17 06:00 [pubmed]
PHST- 2021/04/30 06:00 [medline]
AID - 10.1111/ajco.13584 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2021 Apr;17 Suppl 3:3-11. doi: 10.1111/ajco.13584.